ClinicalTrials.gg
CompletedNCT00021255Updated Nov 15, 2016Results posted

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

A Phase 3 interventional study of Doxorubicin and Cyclophosphamide in Breast Neoplasms, sponsored by Sanofi. Completed at 42 sites in 42 countries. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-11-15.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,222
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 197 studies testing doxorubicin in Breast Neoplasms — 9 open to participants now, 18 under way, 5 of them phase 3. Doxorubicin · Breast Neoplasms.

Enrollment
8th of 189
3,222 · median 56
Started
2001
with 6 others
Phase 3
28 of 197
3 open now
Registered
28th of 197
by date

Among the 197 studies testing doxorubicin in Breast Neoplasms, this one is the 8th largest by enrollment of the 189 interventional ones that give a count, is one of 7 that started in 2001, is one of 28 in phase 3, and was the 28th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

9 of the 197 studies testing doxorubicin in Breast Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About doxorubicin

Doxorubicin: first FDA approval 1974 (DOXORUBICIN HYDROCHLORIDE), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 197 studies testing doxorubicin in Breast Neoplasms, or all of them as a file.
02

Study summary

Primary objective:

  • Compare disease-free survival in women with human epidermal growth factor receptor 2 (HER2)-neu-expressing node-positive or high-risk node-negative operable breast cancer treated with adjuvant doxorubicin, cyclophosphamide, and docetaxel with or without trastuzumab (Herceptin) vs trastuzumab, docetaxel, and carboplatin.

Secondary objective:

  • Compare overall survival of participants treated with these regimens.
  • Compare the toxic effects (including cardiac) of these regimens in these participants.
  • Compare quality of life of participants treated with these regimens.
  • Compare pathologic and molecular markers for predicting efficacy of these regimens in these participants.
  • For substudy: Compare peripheral levels of shed HER2-neu extracellular domain with fluorescence in situ hybridization in predicting outcome in participants treated with these regimens.
03

Conditions studied

  • Breast Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written prior to beginning specific protocol procedures, including expected cooperation of the participants for treatment and follow-up.
  • Accessible for treatment and follow-up at participating centers.
  • proven breast cancer with an interval between definitive surgery that included axillary lymph node involvement assessment and registration of less than or equal to 60 days. A central pathology review might be performed post randomization for confirmation of diagnosis and molecular studies. The same block used for HER2neu determination prior to randomization might be used for the central pathology review.
  • Definitive surgical treatment must be either mastectomy with axillary lymph node involvement assessment, or breast conserving surgery with axillary lymph node involvement assessment for operable breast cancer (T1-3, Clinical N0-1, M0). Margins of resected specimen from definitive surgery must be histologically free of invasive adenocarcinoma and/or ductal carcinoma in situ (DCIS).
  • Participants must be either lymph node positive or high risk node negative. Lymph node positive participants were to be defined as participants having invasive adenocarcinoma with at least one axillary lymph node (pN1) showing evidence of tumor among a minimum of six resected lymph nodes. High risk lymph node negative participants were to be defined as participants having invasive adenocarcinoma with either 0 (pNo) among a minimum of 6 resected lymph nodes or negative sentinel node (pNo) and at least one of the following factors: tumor size > 2 cm, estrogen receptor (ER) and/or progesteron receptor (PR) status was negative, histologic and/or nuclear grade 2-3, or age \< 35 years.
  • Tumor must show the presence of the HER2neu gene amplification by Fluorescence In-Situ Hybridization (FISH analysis) by a designated central laboratory.
  • Estrogen and/or progesterone receptor analysis performed on the primary tumor prior to randomization. Results must be known at the time of randomization.
  • Performance status index ≥ 80%.
  • Normal cardiac function must be confirmed by (LVEF) (multiple-gated acquisition [MUGA] scan) and (ECG) within 3 months prior to registration. The result of the MUGA must be equal to or above the lower limit of normal for the institution.
  • Laboratory requirements: (within 14 days prior to registration)

    a) Hematology: i) Neutrophils ≥ 2.0 109/L ii) ≥ 100 109/L iii) ≥ 10 g/Dl

    b) Hepatic function: i) Total ≤ 1 UNL ii) (ASAT) (Serum glutamic oxaloacetic transaminase [SGOT]) and alanine amino transferase (ALAT) (Serum glutamic-pyruvic transaminase [SGPT]) ≤ 2.5 UNL iii) Alkaline phosphatase ≤ 5 UNL iv) Participants with ASAT and/or ALAT > 1.5 x UNL associated with alkaline phosphatase > 2.5 x UNL are not eligible for the study.

    c) Renal function: i) Creatinine ≤ 175 µmol/L (2 mg/dL) ii) If creatinine was 140 - 175 μmol/L, the calculated should be ≥ 60 mL/min.

  • Complete staging work-up within 3 months prior to registration. All participants had bilateral mammography, chest X-ray (posterioanterior [PA] and lateral) and/or computerized tomography (CT) and/or magnetic resonance imaging (MRI), abdominal ultrasound and/or CT scan and/or MRI, and bone scan. In cases of positive bone scans, bone X-ray evaluation was mandatory to rule out the possibility of bone scan positivity. Other tests may be performed as clinically indicated.
  • Negative pregnancy test (urine or serum) within 7 days prior to registration for all women of .
  • An audiology assessment with normal results was to be performed within 4 weeks of registration. This was only for those centers who had selected cisplatin as their platinum salt of choice for the BCIRG 006 study.

Exclusion criteria

Exclusion criteria:

  • Prior systemic anticancer therapy for breast cancer (immunotherapy, hormonotherapy, chemotherapy).
  • Prior anthracycline therapy, taxoids (paclitaxel, docetaxel) or platinum salts for any .
  • Prior radiation therapy for breast cancer.
  • Bilateral invasive breast cancer.
  • Pregnant, or lactating participants. Participants of must implement adequate non-hormonal measures during study treatment (chemotherapy and tamoxifen therapy) and must had negative urine or serum pregnancy test within 7 days prior to registration.
  • Any T4 or N2 or known N3 or M1 breast cancer.
  • Pre-existing motor or sensory neurotoxicity of a severity ≥ grade 2 by National Cancer Institute (NCI) criteria.
  • Cardiac disease that would preclude the use of doxorubicin, docetaxel and Herceptin:

    1. any documented myocardial infarction
    2. angina pectoris that required the use of antianginal medication
    3. any history of documented congestive heart failure
    4. Grade 3 or Grade 4 cardiac arrhythmia (NCI Common Terminology Criteria [CTC], version 2.0)
    5. valvular heart disease
    6. participants with cardiomegaly on chest x-ray or ventricular hypertrophy on , unless they demonstrate by within the past 3 months that the LVEF was ≥ the lower limit of normal for the radiology facility;
    7. participants with poorly controlled hypertension i.e. diastolic greater than 100 mm/Hg. (Participants who were well controlled on medication were eligible for entry)
    8. participants who currently received medications (digitalis, beta-blockers, calcium channel-blockers, etc) that altered cardiac conduction, if these medications were administered for cardiac arrhythmia, angina or congestive heart failure. If these medications were administered for other reasons (ie hypertension), the participant was eligible.
  • Other serious illness or medical condition:

    1. history of significant neurologic or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of
    2. active uncontrolled infection
    3. active peptic ulcer, unstable diabetes mellitus
    4. impaired hearing (only for those participants treated at centers who had selected cisplatin as their platinum salt of choice)
  • Past or current history of neoplasm other than breast carcinoma, except for:

    1. curatively treated non-melanoma skin cancer
    2. in situ carcinoma of the cervix
    3. other cancer curatively treated and with no evidence of disease for at least 10 years
    4. ipsilateral DCIS of the breast
    5. lobular carcinoma in-situ (LCIS) of the breast
  • Current therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulators (SERMs), either for osteoporosis or prevention. Participants must had discontinued these agents prior to randomization.
  • Chronic treatment with unless initiated > 6 months prior to study entry and at low dose (≤ 20 mg methylprednisolone or equivalent).
  • Concurrent treatment with ovarian hormonal replacement therapy. Prior treatment must be stopped prior to randomization.
  • Definite for the use of corticosteroids.
  • Concurrent treatment with other experimental drugs. Participation in another clinical trial with any not marketed drug within 30 days prior to study entry.
  • Concurrent treatment with any other anti-cancer therapy.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,222 participants (actual)

Study arms

  • Experimental
    Doxorubicin+Cyclophosphamide (AC) followed by Docetaxel (AC→T)

    Doxorubicin 60 mg/m² intravenous (IV) bolus injection in combination with cyclophosphamide 600 mg/m² IV bolus injection on Day 1 of every 3 weeks for 4 cycles followed by docetaxel 100 mg/m² IV infusion every 3 weeks for another 4 cycles.

    Drug: Doxorubicin · Drug: Cyclophosphamide · Drug: Docetaxel

  • Experimental
    AC followed by Docetaxel + Herceptin (AC→TH)

    Doxorubicin 60 mg/m² IV bolus injection in combination with cyclophosphamide 600 mg/m² IV bolus Injection on Day 1 of every 3 weeks for 4 cycles. Herceptin 4 mg/kg IV infusion on Day 1 of Cycle 5, followed by Herceptin 2 mg/kg by IV infusion weekly starting from Day 8; and docetaxel 100 mg/m² IV infusion on Day 2 of Cycle 5, then on Day 1 of every 3 weeks for all subsequent cycles ( total 4 cycles). After completion of the last cycle of chemotherapy, Herceptin 6 mg/kg IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose.

    Drug: Doxorubicin · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Herceptin

  • Experimental
    Docetaxel + Carboplatin + Herceptin (TCH)

    Herceptin 4 mg/kg IV infusion on Day 1 of Cycle 1 only, followed by Herceptin 2 mg/kg IV infusion weekly starting from Day 8 until three weeks after the last cycle of chemotherapy. Docetaxel 75 mg/ m² IV infusion on Day 2 of Cycle 1, then on Day 1 of all subsequent cycles followed by carboplatin IV infusion at target AUC = 6 mg/mL/min repeated every 3 weeks for a total of 6 cycles. After completion of the last cycle of chemotherapy, Herceptin 6 mg/kg by IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose.

    Drug: Docetaxel · Drug: Herceptin · Drug: Carboplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Disease Free Survival at 5 Years

    Disease Free Survival was defined as the interval from the date of randomization to the date of local, regional or metastatic relapse or the date of second primary cancer (with the exception of curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix) or death from any cause whichever occured first. Disease free survival was estimated using the Kaplan-Meier method.

    Time frame: From randomization until relapse or death or up to 5 years

Secondary outcomes

  1. Percentage of Participants With Disease Free Survival at 10 Years

    Disease free survival was defined as the interval from the date of randomization to the date of local, regional or metastatic relapse or the date of second primary cancer (with the exception of curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix) or death from any cause whichever occured first. Disease free survival was estimated using the Kaplan-Meier method.

    Time frame: From randomization until relapse or death or up to 10 years

  2. Overall Survival- Percentage of Participants Who Survived at 10 Years

    Overall survival of the participants was measured from the date of randomization up to the date of death due to any cause. Overall survival was estimated using the Kaplan-Meier method.

    Time frame: From randomization until death or up to 10 years

07

Results

Posted Nov 15, 2016

Participant flow

The study was conducted at 433 centers in 43 countries. A total of 3222 participants randomized between 05 April 2001 and 30 March 2004. Participants stratified according to institution, nodal status(negative, positive 1-3 nodes, positive 4 or more nodes) and hormonal receptor status (estrogen and/or progesterone receptor positive versus negative).

Participant flow — Overall Study
MilestoneDoxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (AC→T)AC Followed by Docetaxel + Herceptin (AC→TH)Docetaxel + Carboplatin + Herceptin (TCH)
Started107310741075
Treated104510721057
Safety population101811001056
Completed952804926
Not completed121270149
Withdrew: Death102
Withdrew: Breast cancer relapse51811
Withdrew: Second primary malignancy041
Withdrew: Withdrawal by subject416426
Withdrew: Lost to follow-up023
Withdrew: Cardiac toxicity06132
Withdrew: Herceptin toxicity0226
Withdrew: Adverse event463018
Withdrew: Protocol violation020
Withdrew: Other than specified above03819
Withdrew: Missing02713
Withdrew: Randomized but not treated28218

Outcome measures

PrimaryPercentage of Participants With Disease Free Survival at 5 Years

Disease Free Survival was defined as the interval from the date of randomization to the date of local, regional or metastatic relapse or the date of second primary cancer (with the exception of curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix) or death from any cause whichever occured first. Disease free survival was estimated using the Kaplan-Meier method.

Time frame:
From randomization until relapse or death or up to 5 years
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Free Survival at 5 Years
percentage of participantsDoxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (AC→T)AC Followed by Docetaxel + Herceptin (AC→TH)Docetaxel + Carboplatin + Herceptin (TCH)
Percentage of Participants With Disease Free Survival at 5 Years75.5 (72.8 to 78.2)83.2 (80.9 to 85.4)81.0 (78.6 to 83.4)
SecondaryPercentage of Participants With Disease Free Survival at 10 Years

Disease free survival was defined as the interval from the date of randomization to the date of local, regional or metastatic relapse or the date of second primary cancer (with the exception of curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix) or death from any cause whichever occured first. Disease free survival was estimated using the Kaplan-Meier method.

Time frame:
From randomization until relapse or death or up to 10 years
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Free Survival at 10 Years
percentage of participantsDoxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (AC→T)AC Followed by Docetaxel + Herceptin (AC→TH)Docetaxel + Carboplatin + Herceptin (TCH)
Percentage of Participants With Disease Free Survival at 10 Years67.2 (64.2 to 70.2)73.4 (70.6 to 76.2)72.3 (69.4 to 75.1)
SecondaryOverall Survival- Percentage of Participants Who Survived at 10 Years

Overall survival of the participants was measured from the date of randomization up to the date of death due to any cause. Overall survival was estimated using the Kaplan-Meier method.

Time frame:
From randomization until death or up to 10 years
Reported as:
Number · percentage of particpants
Overall Survival- Percentage of Participants Who Survived at 10 Years
percentage of particpantsDoxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (AC→T)AC Followed by Docetaxel + Herceptin (AC→TH)Docetaxel + Carboplatin + Herceptin (TCH)
Overall Survival- Percentage of Participants Who Survived at 10 Years78.9 (76.2 to 81.5)86.0 (83.8 to 88.2)83.4 (81.0 to 85.8)

Adverse events

Collected over All Adverse Events (AE) were collected from the time the participant started treatment with study drug until 30 days after the last infusion of study treatment (chemotherapy or Herceptin).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Doxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (AC→T)—218/1,018 (21.4%)1,017/1,018 (99.9%)
AC Followed by Docetaxel + Herceptin (AC→TH)—298/1,100 (27.1%)1,100/1,100 (100%)
Docetaxel + Carboplatin + Herceptin (TCH)—283/1,056 (26.8%)1,052/1,056 (99.6%)
Most frequent serious events
Showing 10 of 145
Most frequent serious events
EventDoxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (AC→T)AC Followed by Docetaxel + Herceptin (AC→TH)Docetaxel + Carboplatin + Herceptin (TCH)
FEVERGeneral disorders85/1018109/110086/1056
INFECTIONGeneral disorders68/101885/110085/1056
LEFT HEART FAILURECardiac disorders8/101825/11002/1056
LEUKOPENIABlood and lymphatic system disorders21/101823/110020/1056
VOMITINGGastrointestinal disorders12/101816/110011/1056
DEEP THROMBOPHLEBITISCardiac disorders6/101813/110015/1056
DIARRHEAGastrointestinal disorders2/101810/110011/1056
CELLULITISGeneral disorders7/10187/110011/1056
ANEMIABlood and lymphatic system disorders1/10188/11009/1056
STOMATITISGastrointestinal disorders7/10184/11001/1056
Most frequent other events
Showing 10 of 60
Most frequent other events
EventDoxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (AC→T)AC Followed by Docetaxel + Herceptin (AC→TH)Docetaxel + Carboplatin + Herceptin (TCH)
ALOPECIASkin and subcutaneous tissue disorders1003/10181083/11001018/1056
NAUSEAGastrointestinal disorders890/1018967/1100863/1056
ASTHENIAGeneral disorders838/1018925/1100878/1056
STOMATITISGastrointestinal disorders660/1018735/1100564/1056
DIARRHEAGastrointestinal disorders439/1018555/1100658/1056
VOMITINGGastrointestinal disorders563/1018628/1100428/1056
MYALGIAMusculoskeletal and connective tissue disorders541/1018614/1100415/1056
NEUROPATHYNervous system disorders514/1018569/1100406/1056
NAIL DISORDERSkin and subcutaneous tissue disorders507/1018484/1100303/1056
ARTHRALGIAMusculoskeletal and connective tissue disorders439/1018515/1100335/1056

Baseline characteristics

Intent-To-Treat (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(years)Doxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (AC→T)AC Followed by Docetaxel + Herceptin (AC→TH)Docetaxel + Carboplatin + Herceptin (TCH)Total
Mean48.8 ± 9.748.7 ± 9.748.6 ± 9.948.7 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Doxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (AC→T)AC Followed by Docetaxel + Herceptin (AC→TH)Docetaxel + Carboplatin + Herceptin (TCH)Total
Female1073107410753222
Male0000
08

Study locations

42 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis Administrative Office
    Buenos Aires, Argentina
  • Sanofi-Aventis Administrative Office
    Macquarie Park, Australia
  • Sanofi-Aventis Administrative Office
    Vienna, Austria
  • Sanofi-Aventis Administrative Office
    Diegem, Belgium
  • Sanofi-Aventis Administrative Office
    Sarajevo, Bosnia and Herzegovina
  • Sanofi-Aventis Administrative Office
    Sao Paulo, Brazil
  • Sanofi-Aventis Administrative Office
    Vazrjdane Region, Bulgaria
  • Sanofi-Aventis Administrative Office
    Québec, Canada
  • Sanofi-Aventis Administrative Office
    Bogota, Colombia
  • Sanofi-Aventis Administrative Office
    Zagreb, Croatia
  • Sanofi-Aventis Administrative Office
    Praha, Czech Republic
  • Sanofi-Aventis Administrative Office
    Cairo, Egypt
  • Sanofi-Aventis Administrative Office
    Tallin, Estonia
  • Sanofi-Aventis Administrative Office
    Paris, France
  • Sanofi-Aventis Administrative Office
    Frankfurt, Germany
  • Sanofi-Aventis Administrative Office
    Kallithea, Greece
  • Sanofi-Aventis Administrative Office
    Hong Kong, Hong Kong
  • Sanofi-Aventis Administrative Office
    Budapest, Hungary
  • Sanofi-Aventis Administrative Office
    Mumbai, India
  • Sanofi-Aventis Administrative Office
    Dublin, Ireland
  • Sanofi-Aventis Administrative Office
    Natanya, Israel
  • Sanofi-Aventis Administrative Office
    Milan, Italy
  • Sanofi-Aventis Administrative Office
    Seoul, Korea, Republic of
  • Sanofi-Aventis Administrative Office
    Beirut, Lebanon
  • Sanofi-Aventis Administrative Office
    Col. Coyoacan, Mexico
  • Sanofi-Aventis Administrative Office
    Macquarie Park, New Zealand
  • Sanofi-Aventis Administrative Office
    Warsaw, Poland
  • Sanofi-Aventis Administrative Office
    Bucuresti, Romania
  • Sanofi-Aventis Administrative Office
    Moscow, Russian Federation
  • Sanofi-Aventis Administrative Office
    Bratislava, Slovakia
  • Sanofi-Aventis Administrative Office
    Ljubljana, Slovenia
  • Sanofi-Aventis Administrative Office
    Gauteng, South Africa
  • Sanofi-Aventis Administrative Office
    Barcelona, Spain
  • Sanofi-Aventis Administrative Office
    Bromma, Sweden
  • Sanofi-Aventis Administrative Office
    Genève, Switzerland
  • Sanofi-Aventis Administrative Office
    Taipei, Taiwan
  • Sanofi-Aventis Administrative Office
    Megrine, Tunisia
  • Sanofi-Aventis Administrative Office
    Istanbul, Turkey
  • Sanofi-Aventis Administrative Office
    Guildford Surrey, United Kingdom
  • Sanofi-Aventis Administrative Office
    Montevideo, Uruguay
  • Sanofi-Aventis Administrative Office
    Caracas, Venezuela
09

References and documents

Publications

  • Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383. PubMed 21991949 ↗
  • Au HJ, Eiermann W, Robert NJ, Pienkowski T, Crown J, Martin M, Pawlicki M, Chan A, Mackey J, Glaspy J, Pinter T, Liu MC, Fornander T, Sehdev S, Ferrero JM, Bee V, Santana MJ, Miller DP, Lalla D, Slamon DJ; Translational Research in Oncology BCIRG 006 Trial Investigators. Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study. Oncologist. 2013;18(7):812-8. doi: 10.1634/theoncologist.2013-0091. Epub 2013 Jun 28. PubMed 23814044 ↗
  • Perez EA, Press MF, Dueck AC, Jenkins RB, Kim C, Chen B, Villalobos I, Paik S, Buyse M, Wiktor AE, Meyer R, Finnigan M, Zujewski J, Shing M, Stern HM, Lingle WL, Reinholz MM, Slamon DJ. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat. 2013 Feb;138(1):99-108. doi: 10.1007/s10549-013-2444-y. Epub 2013 Feb 19. PubMed 23420271 ↗
  • Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Villalobos IE, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Bee V, Taupin H, Flom KJ, Tabah-Fisch I, Pauletti G, Lindsay MA, Riva A, Slamon DJ. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol. 2011 Mar 1;29(7):859-67. doi: 10.1200/JCO.2009.27.5644. Epub 2010 Dec 28. PubMed 21189395 ↗
  • Stern HM, Gardner H, Burzykowski T, Elatre W, O'Brien C, Lackner MR, Pestano GA, Santiago A, Villalobos I, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Nuciforo P, Bee V, Mackey J, Slamon DJ, Press MF. PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. Clin Cancer Res. 2015 May 1;21(9):2065-74. doi: 10.1158/1078-0432.CCR-14-2993. Epub 2015 Feb 3. PubMed 25649019 ↗
  • Press MF, Sauter G, Buyse M, Fourmanoir H, Quinaux E, Tsao-Wei DD, Eiermann W, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Mackey JR, Bee V, Ma Y, Villalobos I, Campeau A, Mirlacher M, Lindsay MA, Slamon DJ. HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials. J Clin Oncol. 2016 Oct 10;34(29):3518-3528. doi: 10.1200/JCO.2016.66.6693. PubMed 27573653 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2001, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2001
First posted
Jan 27, 2003
Start
Apr 2001
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
Nov 15, 2016
Last update
Nov 15, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00021255
Lead sponsor
Sanofi
Collaborators
Cancer International Research Group (CIRG)
Responsible party
Sponsor
First posted
Jan 27, 2003
Start date
Apr 2001
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Nov 15, 2016
Last update
Nov 15, 2016

Study contacts

AUSSEL Jean Philippe
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Doxorubicin · Cyclophosphamide · Trastuzumab · Carboplatin

Start the discussion